28 de abril de 2017 / 13:26 / en 5 meses

BRIEF-TG Therapeutics announces preliminary results from ongoing Phase 2 study of TG-1101

April 28 (Reuters) - TG Therapeutics Inc

* TG Therapeutics announces preliminary results from ongoing Phase 2 study of TG-1101 (ublituximab) in patients with multiple sclerosis at the American Academy of Neurology 69th annual meeting

* TG Therapeutics Inc - tg-1101 was well tolerated with no grade 3/4 adverse events reported, with median time on study of 5 months

* TG Therapeutics Inc - believe this Phase 2 trial sets stage for our Phase 3 program that we expect to commence in coming months

* TG Therapeutics Inc - MS patients treated with TG-1101 exhibited median B-cell depletion of 99 pct at week 4 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below